Emergent BioSolutions Inc <EBS.N>: Profits of 4 cents per share anticipated for fourth quarter

Jan 26 (Reuters) - Marker Therapeutics Inc: * MARKER THERAPEUTICS INC - FILED 1-FOR-10 REVERSE STOCK SPLIT, REDUCTION IN TOTAL NUMBER OF AUTHORIZED SHARES OF COMMON STOCK TO 30 MILLION * MARKER

Jan 26 (Reuters) - Solid Biosciences Inc: * SOLID BIOSCIENCES INC FILES FOR RESALE OF UP TO ABOUT 12 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Further company coverage:

Jan 26 (Reuters) - ContraFect Corp: * CONTRAFECT CORP - ON JAN 20, NASDAQ STAFF INFORMED CO THAT STAFF HAD DETERMINED TO DENY CO'S REQUEST FOR CONTINUED LISTING ON NASDAQ CAPITAL MARKET Further

Jan 26 (Reuters) - Sana Biotechnology Inc: * SANA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR SC291, A HYPOIMMUNE-MODIFIED, CD19-TARGETED ALLOGENEIC CAR T THERAPY

Jan 26 (Reuters) - Kronos Bio Inc: * KRONOS BIO INC - ON JAN 21 MARIANNE DE BACKER, NOTIFIED DECISION TO RESIGN FROM BOARD AS A RESULT OF HER APPOINTMENT AS CEO OF VIR BIOTECHNOLOGY * KRONOS BIO INC -

Jan 26 (Reuters) - Moderna Inc: * FDA ADVISERS VOTE IN FAVOR OF USING SAME CORONAVIRUS VARIANT FOR INITIAL COVID VACCINE DOSES AND BOOSTERS Further company coverage:

Jan 26 (Reuters) - Moderna Inc: * NOVAVAX OFFICIAL SEEKS SIX MONTH TIME PERIOD FROM PROVIDING COVID STRAIN SELECTION TO DELIVERING PRODUCT * NOVAVAX OFFICIALS TELLS FDA THAT SIX MONTH PERIOD IS

By Leroy Leo (Reuters) - Novavax Inc said on Thursday it would require six months to produce a COVID-19 vaccine designed to match whichever coronavirus variants are circulating for an annual

(Adds company comments) Jan 26 (Reuters) - The U.S. Food and Drug Administration on Thursday classified the recall of Emergent BioSolutions Inc's skin decontamination lotion kits as the most serious

Jan 26 (Reuters) - Emergent BioSolutions Inc: * EMERGENT SAYS AFTER BECOMING AWARE THAT SMALL NUMBER OF RSDL PACKETS HAD LEAKED, NOTIFIED U.S. FDA OTHER GOVERNMENT AGENCIES, &amp; CUSTOMERS - SPOKESPERSON